Prescribing information (package insert) - Pertzye
1 INDICATIONS AND USAGE
PERTZYE® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients.
2 DOSAGE AND ADMINISTRATION
2.1 Important Dosing Information
PERTZYE is a mixture of enzymes including lipases, proteases, and amylases. PERTZYE dosing is based on lipase units.
- Use either an actual body weight or fat ingestion-based dosing scheme.
- Start at the lowest recommended dosage and individualize the dosage based on clinical symptoms, the degree of steatorrhea present, and the fat content of the diet. Changes in dosage may require an adjustment period of several days.
- Do not exceed 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation [see Warnings and Precautions (5.1)].
- The total daily dosage in adult and pediatric patients greater than 12 months of age should reflect approximately three meals plus two or three snacks per day. With each snack, administer approximately half the prescribed PERTZYE dose for a meal.
- Do not substitute other pancreatic enzyme products for PERTZYE. When switching from another pancreatic enzyme product to PERTZYE, monitor patients for clinical symptoms of exocrine pancreatic insufficiency and titrate the dosage as needed.
2.2 Recommended Dosage
Adults and Pediatric Patients Greater than 12 Months of Age
The recommended oral initial starting dosage is:
- 500 lipase units/kg/meal for adult and pediatric patients 4 years of age and older.
- 1,000 lipase units/kg/meal for pediatric patients greater than 12 months to less than 4 years of age.
If signs and symptoms of malabsorption persist, increase the dosage. Titrate to either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/gram of fat ingested/day. Higher dosages may be administered if they are documented to be effective by fecal fat measures or an improvement in signs or symptoms of malabsorption including measures of nutritional status.
Pediatric Patients Birth to 12 Months of Age
The recommended oral dosage is 4,000 lipase units per 120 mL of formula or per breastfeeding.
2.3 Preparation and Administration Instructions
Adult and Pediatric Patients Greater than 12 Months of Age
Instruct adult and pediatric patients greater than 12 months of age, or their caregivers, of the following:
- Take PERTZYE with meals or snacks. If a dose is missed, take the next dose with the next meal or snack.
- Swallow capsules whole.
- For patients unable to swallow intact capsules, the capsule contents may be sprinkled on a small amount of soft acidic food with a pH of 4.5 or less (e.g., applesauce). The 4,000 USP lipase unit capsule may also be administered with applesauce via gastrostomy tube 14 French or larger.
- Do not crush or chew PERTZYE capsules or capsule contents.
- Consume sufficient liquids (water or juice) to ensure complete swallowing of PERTZYE [see Warnings and Precautions (5.2)].
Oral Administration for Patients Unable to Swallow Intact Capsules
- 1. Carefully open the capsules and sprinkle the entire contents on a small amount of acidic soft food (approximately 10 mL) with a pH of 4.5 or less (e.g., applesauce).
- 2. Mix the capsule contents with the acidic soft food (e.g., applesauce) being careful not to crush the contents.
- 3. Consume the entire mixture immediately. Do not save the mixture for later use.
- 4. Consume sufficient fluids to ensure complete swallowing of the PERTZYE food mixture.
Gastrostomy Tube Administration (14 French Gastrostomy Tube or Larger)
- Only perform gastrostomy tube administration with the contents of the 4,000 USP lipase unit capsule of PERTZYE.
The contents of no more than two capsules may be administered at a time in the gastrostomy tube.
- 1. Transfer a minimum of 10 mL of applesauce into a small bowl or medicine cup.
- 2. Carefully open one or two PERTZYE 4,000 lipase unit capsules.
- 3. Mix the capsule contents thoroughly with the transferred applesauce to create a uniform suspension being careful not to crush the contents. Once mixed, administer the suspension immediately.
- 4. Remove the plunger from a 35 mL slip tip syringe. Cover the tip of the syringe with your finger. Transfer the PERTZYE-applesauce mixture into the syringe. Replace the plunger partially back into the syringe.
- 5. Shake or tap the syringe lightly with the syringe tip facing upward so that the PERTZYE-applesauce mixture will move towards the plunger. Carefully push the plunger slowly until the residual air is removed from the syringe tip.
- 6. Once the residual air is removed, connect the syringe directly into the gastrostomy tube feeding port.
- 7. Push the syringe contents into the gastrostomy tube feeding port using steady pressure until empty.
- 8. Draw up approximately 10 mL of water with the slip tip syringe and flush the gastrostomy tube feeding port with the water.
- 9. Discard any unused portion of the PERTZYE-applesauce mixture. Do not save for later use.
- 10. If dose requires more than two capsules, repeat steps 1-9 until prescribed dose is reached.
Pediatric Patients Birth to 12 Months of Age:
Instruct caregivers of pediatric patients birth to 12 months of age of the following:
Immediately prior to each breastfeeding session or each administration of 120 mL of formula, carefully open one PERTZYE capsule (containing 4,000 USP units of lipase) and administer the entire contents using one of the following two methods:
- Sprinkle on a small amount of acidic soft food with a pH of 4.5 or less (e.g., applesauce) being careful not to crush the capsule contents. The entire mixture should be given to the infant immediately.
- Sprinkle the capsule contents directly into the infant's mouth.
- Immediately administer breast milk or formula after PERTZYE to ensure complete swallowing of the PERTZYE capsule contents.
- Do not crush PERTZYE capsule contents, and visually inspect the infant's mouth to ensure that no drug is retained in the mouth [see Warnings and Precautions (5.2)].
- If a dose is missed, administer the next dose with the next feeding.
3 DOSAGE FORMS AND STRENGTHS
Delayed-release capsules are available in the following strengths:
- 4,000 USP units of lipase; 14,375 USP units of protease; and 15,125 USP units of amylase in a two-piece hard gelatin capsule with a clear body printed in green with "4" and a clear cap printed with a green circular stripe and "DCI"
- 8,000 USP units of lipase; 28,750 USP units of protease; and 30,250 USP units of amylase in a two-piece hard gelatin capsule with a clear body printed in blue with "8" and a clear cap printed with a blue circular stripe and "DCI"
- 16,000 USP units of lipase; 57,500 USP units of protease; and 60,500 USP units of amylase in a two-piece hard gelatin capsule with a clear body printed in red with "16" and a clear cap printed with a red circular stripe and "DCI"
- 24,000 USP units of lipase; 86,250 USP units of protease; and 90,750 USP units of amylase in a two-piece hard gelatin capsule with a clear body printed in purple with "24" and a clear cap printed with a purple circular stripe and "DCI"
4 CONTRAINDICATIONS
None.
5 WARNINGS AND PRECAUTIONS
5.1 Fibrosing Colonopathy
Fibrosing colonopathy has been reported following treatment with pancreatic enzyme products. Fibrosing colonopathy is a rare, serious adverse reaction initially described in association with use of high-dose pancreatic enzyme products, usually with use over a prolonged period of time and most commonly reported in pediatric patients with cystic fibrosis. Pancreatic enzyme products exceeding 6,000 lipase units/kg/meal have been associated with colonic stricture, a complication of fibrosing colonopathy, in pediatric patients less than 12 years of age. The underlying mechanism of fibrosing colonopathy remains unknown.
If there is a history of fibrosing colonopathy, monitor patients during treatment with PERTZYE because some patients may be at risk of progressing to colonic stricture formation. It is uncertain whether regression of fibrosing colonopathy occurs. Do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in adult and pediatric patients greater than 12 months of age without further investigation. Higher dosages may be administered if they are documented to be effective by fecal fat measures or an improvement in signs and symptoms of malabsorption including measures of nutritional status. Patients receiving dosages higher than 6,000 lipase units/kg/meal should be frequently monitored for symptoms of fibrosing colonopathy and the dosage decreased or titrated downward to a lower range if clinically appropriate [see Dosage and Administration (2.1)].
5.2 Irritation of the Oral Mucosa
Crushing or chewing PERTZYE capsules or mixing the capsule contents in foods having a pH greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity.
Instruct the patient or caregiver of the following:
- Swallow capsules whole. For patients who cannot swallow the capsules whole, the capsules can be opened, and the contents sprinkled on a small amount of acidic soft food with a pH of 4.5 or less (e.g., applesauce). The 4,000 USP lipase unit capsule may also be administered with applesauce via a gastrostomy tube with a diameter of 14 French or larger.
- Do not crush or chew PERTZYE capsules or capsule contents.
- Consume sufficient liquids (juice, water, breast milk, or formula) immediately following administration of PERTZYE to ensure complete swallowing.
- Visually inspect the mouth of pediatric patients less than 12 months of age and of patients who are unable to swallow intact capsules to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see Dosage and Administration (2.3)].
5.3 Hyperuricemia
Pancreatic enzyme products contain purines that may increase blood uric acid levels. High dosages have been associated with hyperuricosuria and hyperuricemia [see Overdosage (10)]. Consider monitoring blood uric acid levels in patients with gout, renal impairment, or hyperuricemia during treatment with PERTZYE.
5.4 Risk of Viral Transmission
PERTZYE is sourced from pancreatic tissue from swine used for food consumption. Although the risk that PERTZYE will transmit an infectious agent to humans has been reduced by testing for certain viruses during manufacturing and by inactivating certain viruses during manufacturing, there is a theoretical risk for transmission of viral disease, including diseases caused by novel or unidentified viruses. Thus, the presence of porcine viruses that might infect humans cannot be definitely excluded. However, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.
5.5 Hypersensitivity Reactions
Severe hypersensitivity reactions including anaphylaxis, asthma, hives, and pruritus have been reported with pancreatic enzyme products [see Adverse Reactions (6.2)]. If symptoms occur, initiate appropriate medical management.
Monitor patients with a known hypersensitivity reaction to proteins of porcine origin for hypersensitivity reactions during treatment with PERTZYE. The risks and benefits of continued PERTZYE treatment in patients with severe hypersensitivity reactions should be taken into consideration with the overall clinical needs of the patient.
6 ADVERSE REACTIONS
The following serious or otherwise important adverse reactions are described elsewhere in the labeling:
- Fibrosing Colonopathy [see Warnings and Precautions (5.1)]
- Irritation of the Oral Mucosa [see Warnings and Precautions (5.2)]
- Hyperuricemia [see Warnings and Precautions (5.3)]
- Risk of Viral Transmission [see Warnings and Precautions (5.4)]
- Hypersensitivity Reactions [see Warnings and Precautions (5.5)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to the rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
The data described below reflect exposure to PERTZYE in 21 patients, aged 8 to 43 years, with exocrine pancreatic insufficiency due to cystic fibrosis in a placebo-controlled clinical trial [see Clinical Studies (14)].
Table 1 enumerates adverse reactions that occurred in at least 2 patients (greater than or equal to 10%) treated with PERTZYE at a higher rate than with placebo.
Table 1. Adverse ReactionsReported in at least 2 PERTZYE-treated patients (≥10%) and at a higher rate than placebo-treated patients in a Clinical Trial of Adult and Pediatric Patients 8 Years of Age and Older with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis
| Adverse Reaction | PERTZYE N=21 (%) | Placebo N=24 (%) |
|---|---|---|
| Diarrhea | 10% | 4% |
| Dyspepsia | 10% | 4% |
| Cough | 10% | 4% |
6.2 Postmarketing Experience
The following adverse reactions have been identified during post-approval use of PERTZYE or other pancreatic enzyme products. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Eye Disorders
- blurred vision
Gastrointestinal Disorders
- fibrosing colonopathy, distal intestinal obstruction syndrome
- abdominal pain, flatulence, constipation, and nausea
Immune System Disorders
- anaphylaxis, asthma, hives, and pruritus
Investigations
- asymptomatic elevations of liver enzymes
Musculoskeletal System
- myalgia, muscle spasm
Skin and Subcutaneous Tissue Disorders
- urticaria and rash
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
Published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. Pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. Animal reproduction studies have not been conducted with pancrelipase.
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
8.2 Lactation
Risk Summary
There are no data on the presence of pancrelipase in either human or animal milk, the effects on the breastfed infant or the effects on milk production. Pancrelipase is minimally absorbed systemically following oral administration, therefore maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for PERTZYE and any potential adverse effects on the breastfed infant from PERTZYE or from the underlying maternal condition.
8.4 Pediatric Use
The safety and effectiveness of PERTZYE for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients.
Use of PERTZYE for this indication is supported by a randomized, double-blind, placebo-controlled, crossover study of 24 pediatric patients, 8 years and older with exocrine pancreatic insufficiency due to cystic fibrosis. The safety in pediatric patients was similar to that observed in adult patients [see Adverse Reactions (6.1) and Clinical Studies (14)].
Dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. If there is a history of fibrosing colonopathy, monitor patients during treatment with PERTZYE because some patients may be at risk of progressing to stricture formation. Do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)].
Crushing or chewing PERTZYE capsules or mixing the capsule contents in foods having a pH greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. Instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure that no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].
8.5 Geriatric Use
Clinical studies of PERTZYE did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between patients aged 65 years and over and younger adult patients.
10 OVERDOSAGE
Chronic high dosages of pancreatic enzyme products have been associated with fibrosing colonopathy and colonic strictures [see Warnings and Precautions (5.1)]. High dosages of pancreatic enzyme products have been associated with hyperuricosuria and hyperuricemia [see Warnings and Precautions (5.3)].
11 DESCRIPTION
Pancrelipase is a pancreatic enzyme product consisting of a mixture of enzymes including lipases, proteases, and amylases, and is an extract derived from porcine pancreatic glands. The enteric-coated microspheres in PERTZYE are formulated to release pancreatic enzymes at an approximate pH of 5.5 or greater.
PERTZYE (pancrelipase) delayed-release capsules are for oral administration, include a two-piece hard gelatin shell containing light tan/cream-colored bicarbonate-buffered enteric-coated microspheres ranging in size from 0.8 to 1.4 mm in diameter for 4,000 USP units of lipase and 0.8 to 2.2 mm in diameter for 8,000, 16,000, and 24,000 USP units of lipase, and are available as follows:
4,000 USP units of lipase; 14,375 USP units of protease; and 15,125 USP units of amylase; delayed-release capsules have a clear body printed in green with "4" and a clear cap printed with a green circular stripe and "DCI". The imprinting ink on the capsule contains FD&C Blue #1, D&C Yellow #10, black iron oxide, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, shellac, and ammonium hydroxide.
8,000 USP units of lipase; 28,750 USP units of protease; and 30,250 USP units of amylase; delayed-release capsules have a clear body printed in blue with "8" and a clear cap printed with a blue circular stripe and "DCI". The imprinting ink on the capsule contains FD&C Blue #1, ethanol, methanol, n-butyl alcohol, propylene glycol, shellac, and ammonium hydroxide.
16,000 USP units of lipase; 57,500 USP units of protease; and 60,500 USP units of amylase; delayed-release capsules have a clear body printed in red with "16" and a clear cap printed with a red circular stripe and "DCI". The imprinting ink on the capsule contains FD&C Red #40, povidone, titanium dioxide, dehydrated alcohol, sodium hydroxide, butyl alcohol, propylene glycol, isopropyl alcohol, and shellac.
24,000 USP units of lipase; 86,250 USP units of protease; and 90,750 USP units of amylase; delayed-release capsules have a clear body printed in purple with "24" and a clear cap printed with a purple circular stripe and "DCI". The imprinting ink on the capsule contains FD&C Blue #2, D&C Red #7, titanium dioxide, strong ammonia solution, propylene glycol, butyl alcohol, isopropyl alcohol, dehydrated alcohol, and shellac.
PERTZYE (pancrelipase) delayed-release capsules include the following inactive ingredients: cellulose acetate phthalate, diethyl phthalate, polyvinylpyrrolidone, sodium bicarbonate, sodium carbonate, sodium starch glycolate, talc, and ursodiol.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Pancreatic enzyme products contain a mixture of lipases, proteases, and amylases that catalyze the hydrolysis of fats to monoglyceride, glycerol and free fatty acids, proteins into peptides and amino acids, and starches into dextrins and short chain sugars such as maltose and maltotriose in the duodenum and proximal small intestine, thereby acting like digestive enzymes physiologically secreted by the pancreas.
12.2 Pharmacodynamics
For patients consuming a high fat diet in the clinical trials, the coefficient of fat absorption (CFA) was higher in patients who received PERTZYE compared to the placebo treatment group, indicating improved fat absorption [see Clinical Studies (14)].
12.3 Pharmacokinetics
Following oral administration, the lipases, proteases, and amylases released from PERTZYE are not absorbed from the gastrointestinal tract in appreciable amounts.
Drug Interactions
The lipases, proteases, and amylases of PERTZYE are not substrates of CYP enzymes or transporters. CYP enzyme or transporter mediated drug interactions are not expected.
14 CLINICAL STUDIES
Adult and Pediatric Patients
A randomized, double-blind, placebo-controlled, crossover study was conducted in 24 patients aged 8 to 43 years (mean age of 20 years) with exocrine pancreatic insufficiency due to cystic fibrosis. Patients were randomized to receive PERTZYE at individually titrated doses (not to exceed 2,500 lipase units/kg/meal) or matching placebo for 6 to 8 days of treatment, followed by crossover to the alternate treatment for an additional 6 to 8 days. The mean lipase dosage during the treatment period was 1,565 lipase units/kg/meal and a controlled high-fat diet (approximately 2g fat/kg/day) was maintained throughout the study. The length of exposure to PERTZYE during this study was 20 to 28 days, including the treatment period of 6 to 8 days, and the open label titration and transition periods of 7 to 10 days each.
The efficacy analysis population included 21 patients who completed both double-blind treatment periods.
Coefficient of Fat Absorption Endpoint and Results
The primary efficacy endpoint was the mean difference in coefficient of fat absorption (CFA) between PERTZYE and placebo treatment. The CFA was determined by a 72-hour stool collection during both treatments, when both fat ingestion and excretion were measured.
Mean CFA was 83% with PERTZYE treatment compared to 46% with placebo treatment. The mean difference in CFA was 36 percentage points in favor of PERTZYE treatment with 95% CI: (28, 45) and p<0.001.
Coefficient of Nitrogen Absorption Endpoint and Results
The coefficient of nitrogen absorption (CNA) was determined by a 72-hour stool collection during both treatments, when nitrogen excretion was measured and nitrogen ingestion from a controlled diet was estimated (based on the assumption that proteins contain 16% nitrogen). Each patient's CNA during placebo treatment was used as their no-treatment CNA value.
Mean CNA was 79% with PERTZYE treatment compared to 47% with placebo treatment. The mean difference in CNA was 32 percentage points in favor of PERTZYE treatment and this was a statistically significant change.
There were no differences between pediatric patients and adults in the severity of pancreatic insufficiency (placebo response) or in the magnitude of the response to PERTZYE.
16 HOW SUPPLIED/STORAGE AND HANDLING
PERTZYE (pancrelipase) delayed-release capsules, containing light tan/cream-colored delayed-release microspheres are supplied as follows:
| Strength | Description | Supplied As | NDC Number |
|---|---|---|---|
4,000 USP units of lipase; 14,375 USP units of protease; 15,125 USP units of amylase | Two-piece hard gelatin capsule with a clear body printed in green with "4" and a clear cap printed with a green circular stripe and "DCI" | Bottles of 100 | 59767-004-01 |
8,000 USP units of lipase; 28,750 USP units of protease; 30,250 USP units of amylase | Two-piece hard gelatin capsule with a clear body printed in blue with "8" and a clear cap printed with a blue circular stripe and "DCI" | Bottles of 100 Bottles of 250 | 59767-008-01 59767-008-02 |
16,000 USP units of lipase; 57,500 USP units of protease; 60,500 USP units of amylase | Two-piece hard gelatin capsule with a clear body printed in red with "16" and a clear cap printed with a red circular stripe and "DCI" | Bottles of 100 Bottles of 250 | 59767-016-01 59767-016-02 |
24,000 USP units of lipase; 86,250 USP units of protease; 90,750 USP units of amylase | Two-piece hard gelatin capsule with a clear body printed in purple with "24" and a clear cap printed with a purple circular stripe and "DCI" | Bottles of 80 Bottles of 200 | 59767-024-01 59767-024-02 |
Storage and Handling
- Store PERTZYE at room temperature 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 40°C (59°F to 104°F) for up to 30 days. PERTZYE hard gelatin capsules should be stored in a dry place in the original container or equivalent airtight container. After opening, keep the container tightly closed between uses to protect from moisture.
- PERTZYE is dispensed in bottles containing a desiccant.
17 PATIENT COUNSELING INFORMATION
Advise the patient or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
Fibrosing Colonopathy
Advise the patient or caregiver that fibrosing colonopathy has been reported with high dosages of pancreatic enzyme products, usually with use over a prolonged period of time and in pediatric patients less than 12 years of age. Advise patients and caregivers that if signs and symptoms of colon stricture formation occur (e.g., stomach area (abdominal) pain, bloating, trouble passing stool (constipation), nausea, vomiting, diarrhea) to immediately contact their healthcare provider [see Warnings and Precautions (5.1)].
Hyperuricemia
Advise the patient or caregiver that hyperuricemia may occur in patients with gout or renal impairment and to contact the healthcare provider if they experience pain, stiffness, redness or swelling of their joints [see Warnings and Precautions (5.3)].
Hypersensitivity Reactions
Inform the patient or caregiver that severe hypersensitivity reactions, including anaphylaxis, asthma, hives, and pruritus, have been reported with use of pancreatic enzyme products. Seek medical attention if signs or symptoms of a hypersensitivity reaction develop [see Warnings and Precautions (5.5)].
Dosage
Advise the patient or caregiver to take or administer PERTZYE as prescribed, and to contact the healthcare provider if signs and symptoms of malabsorption persist [see Dosage and Administration (2.2)].
Administration
Instruct the patient or caregiver to:
- Take PERTZYE with meals or snacks.
- Swallow capsules whole.
For patients unable to swallow intact capsules:
- the capsule contents may be sprinkled on a small amount of soft acidic food with a pH of 4.5 or less (e.g., applesauce). The 4,000 USP lipase unit capsule may also be administered with applesauce via gastrostomy tube 14 French or larger.
- For pediatric patients birth to 12 months of age, PERTZYE capsules can be opened, and the capsule contents sprinkled directly into the infant's mouth.
- See the Instructions for Use for a description of all preparation and administration instructions.
- Consume sufficient liquids (juice, water, breast milk, or formula) and visually inspect an infant's mouth to ensure complete swallowing of PERTZYE capsules or capsule contents [see Warnings and Precautions (5.2)].
- Do not crush or chew PERTZYE capsules or capsule contents.
- Do not mix the PERTZYE capsule contents directly into a bottle of breast milk or formula.
Storage
Instruct the patient or caregiver as follows:
- Keep PERTZYE in a dry place and protect from moisture and heat.
- After opening, keep the container tightly closed between uses to protect from moisture.
- The desiccant packet should not be eaten or thrown away.
Manufactured by:
Digestive Care, Inc.
1120 Win Drive
Bethlehem, PA 18017
U.S. License No. 2184
Product of USA
PERTZYE® is a registered trademark of Digestive Care, Inc.
U.S. Patent Numbers: 5,260,074; 5,302,400; 5,324,514; 5,460,812; 5,578,304; 5,750,104
